Tecfidera Takes Off In U.S., Clarity For EU Launch Likely Soon
This article was originally published in The Pink Sheet Daily
Executive Summary
Biogen Idec’s launch of the drug continued to surpass Wall Street’s expectations, in its third quarter earnings. Its potential EU marketing of Tecfidera hangs in the balance, with news likely on Nov. 22 from CHMP. The biotech also highlighted its approval and pipeline expectations for 2014.